TABLE 6.
Design of single and multiple once-weekly rising-dose trial of MK-8507 with midazolam interaction arm (study 2)
| Panel | No. of patientsa | Treatment at day −1 | Single-dose treatment at: |
Multiple-dose treatment at: |
|
|---|---|---|---|---|---|
| Day 1 | Days 22 and 29 | Day 36b | |||
| A | 8 | 400 mg MK-8507 or placebo | 100 mg MK-8507 or placebo | 100 mg MK-8507 or placebo | |
| B | 8 | 800 mg MK-8507 or placebo | 200 mg MK-8507 or placebo | 200 mg MK-8507 or placebo | |
| C | 8 | 2 mg midazolam | 1,200 mg MK-8507 or placebo | 400 mg MK-8507 or placebo | 400 mg MK-8507 or placebo and 2 mg midazolam |
a
Randomized, double-blind, 3:1 active treatment/placebo.
b
Final safety evaluation (21 days from last dose).